SNJ-1945, a calpain inhibitor, protects SH-SY5Y cells against MPP(+) and rotenone

Journal of Neurochemistry
V H KnaryanNaren L Banik

Abstract

Complex pathophysiology of Parkinson's disease involves multiple CNS cell types. Degeneration in spinal cord neurons alongside brain has been shown to be involved in Parkinson's disease and evidenced in experimental parkinsonism. However, the mechanisms of these degenerative pathways are not well understood. To unravel these mechanisms SH-SY5Y neuroblastoma cells were differentiated into dopaminergic and cholinergic phenotypes, respectively, and used as cell culture model following exposure to two parkinsonian neurotoxicants MPP(+) and rotenone. SNJ-1945, a cell-permeable calpain inhibitor was tested for its neuroprotective efficacy. MPP(+) and rotenone dose-dependently elevated the levels of intracellular free Ca(2+) and induced a concomitant rise in the levels of active calpain. SNJ-1945 pre-treatment significantly protected cell viability and preserved cellular morphology following MPP(+) and rotenone exposure. The neurotoxicants elevated the levels of reactive oxygen species more profoundly in SH-SY5Y cells differentiated into dopaminergic phenotype, and this effect could be attenuated with SNJ-1945 pre-treatment. In contrast, significant levels of inflammatory mediators cyclooxygenase-2 (Cox-2 and cleaved p10 fragment of c...Continue Reading

References

Nov 1, 1983·Neurochemical Research·N L BanikM B Sostek
Sep 18, 1997·Acta Neuropathologica·K Wakabayashi, H Takahashi
Sep 29, 1999·Proceedings of the National Academy of Sciences of the United States of America·D C ShieldsN L Banik
Mar 21, 2000·The Journal of Comparative Neurology·A Mouatt-PrigentE C Hirsch
Jul 10, 2002·Annals of the New York Academy of Sciences·Bhisham CheraNaren L Banik
Apr 19, 2003·Proceedings of the National Academy of Sciences of the United States of America·Peter TeismannSerge Przedborski
Nov 27, 2007·Journal of Neurochemistry·Supriti SamantarayNaren L Banik
Mar 8, 2008·Neurobiology of Aging·Diego MastroeniJoseph Rogers
Aug 5, 2008·CNS & Neurological Disorders Drug Targets·Supriti SamantarayNaren L Banik
Dec 9, 2008·Biochimica Et Biophysica Acta·Rebecca BanerjeeBobby Thomas
Oct 28, 2009·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Hong MaMitsuyoshi Azuma
Dec 8, 2009·American Journal of Physiology. Heart and Circulatory Physiology·Yoshiro YoshikawaMiyako Takaki
Dec 26, 2009·Neurobiology of Disease·A Raquel EstevesSandra M Cardoso
Mar 23, 2010·Cell·Christopher K GlassFred H Gage
Mar 12, 2011·Journal of Chemical Neuroanatomy·Giorgio VivacquaLoredana D'Este
May 15, 2012·Journal of Chemical Neuroanatomy·Giorgio VivacquaFrancesco Fornai
Aug 29, 2012·Acta Neuropathologica·Kelly Del Tredici, Heiko Braak
Dec 18, 2012·The Journal of Physiological Sciences : JPS·D TakeshitaMiyako Takaki
May 28, 2013·Journal of Toxicology·João Barbosa MartinsJoão Paulo Capela
Jul 24, 2013·Journal of Neurochemistry·Supriti SamantarayNaren L Banik
Sep 3, 2013·Therapeutic Advances in Neurological Disorders·Stefan Bittner, Sven G Meuth

❮ Previous
Next ❯

Citations

Sep 17, 2015·Journal of Neurochemistry·Anna WilkaniecAgata Adamczyk
Jan 30, 2015·Neurotoxicity Research·Juan Segura-Aguilar, Richard M Kostrzewa
Nov 12, 2016·Nature Reviews. Drug Discovery·Yasuko OnoHiroyuki Sorimachi
Dec 3, 2016·European Journal of Pharmacology·Junyao LiGuoqi Zhu
Jan 26, 2017·Molecular Neurodegeneration·Helena XicoyGerard J M Martens
Aug 27, 2018·Journal of Cellular Physiology·Omid Reza TamtajiZatollah Asemi
Jun 28, 2016·Scientific Reports·Charles L HoweEric J Buenz
Jul 11, 2020·Aging·Jinyu ZhengJian Sun
Nov 11, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Da Hye SongJeung Hee An
Jul 26, 2019·Molecular and Cellular Biochemistry·Jian-Liang ZhuChun-Feng Liu
Oct 16, 2020·International Journal of Molecular Sciences·Md Ezazul HaqueIn-Su Kim
Jun 17, 2021·The European Journal of Neuroscience·Xianwen ZhangJie Bai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atypical Parkinsonism (MDS)

Atypical Parkinsonism presents with the same signs and symptoms of Parkinson's disease, but do not respond to typical Parkionson's disease treatment with levodopa. Atypical Parkinsonism is thought to be associated with abnormal protein buildup within brain cells. Here is the latest on Atypical Parkinsonism.